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Summary
We have developed a real-time quantitative PCR assay
to measure the concentration of fetal DNA in maternal
plasma and serum. Our results show that fetal DNA is
present in high concentrations in maternal plasma,
reaching a mean of 25.4 genome equivalents/ml (range
3.3–69.4) in early pregnancy and 292.2 genome equiv-
alents/ml (range 76.9–769) in late pregnancy. These con-
centrations correspond to 3.4% (range 0.39%–11.9%)
and 6.2% (range 2.33%–11.4%) of the total plasma
DNA in early and late pregnancy, respectively. Sequential
follow-up study of women who conceived by in vitro
fertilization shows that fetal DNA can be detected in
maternal serum as early as the 7th wk of gestation and
that it then increases in concentration as pregnancy pro-
gresses. These data suggest that fetal DNA can be readily
detected in maternal plasma and serum and may be a
valuable source of material for noninvasive prenatal
diagnosis.
Introduction
Noninvasive prenatal diagnosis is a long-sought goal in
human genetics. The passage of fetal nucleated cells into
maternal blood is a well-recognized phenomenon (Walk-
nowska et al. 1969; Lo et al. 1989; Lo et al. 1996), and
it makes possible the use of these cells for noninvasive
prenatal diagnosis (Simpson and Elias 1993). Significant
advances have been made in the enrichment and isola-
tion of fetal cells for analysis (Bianchi et al. 1990;
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Cheung et al. 1996). However, most techniques are time
consuming, labor intensive, or difficult to implement on
a large scale. These limitations prompted us to investi-
gate alternative sources of fetal genetic material for mo-
lecular analysis.
There has been much recent interest in the use of DNA
derived from plasma or serum, for molecular diagnosis
(Boland 1996). In particular, plasma and serum DNA
from cancer patients has been shown to contain large
quantities of tumor DNA (Chen et al. 1996; Nawroz et
al. 1996; Anker et al. 1997). Prompted by such reports,
we recently demonstrated that fetal DNA is present in
maternal plasma and serum (Lo et al. 1997). Detection
of fetal DNA sequences was possible, in 80% and 70%
of cases, with just 10 ml of boiled plasma and serum,
respectively (Lo et al. 1997).
These observations suggest that maternal plasma/se-
rum DNA may be a useful source of material for the
noninvasive prenatal diagnosis of certain genetic disor-
ders. However, a number of important questions need
to be answered before clinical application of this new
approach can be contemplated. First, fetal DNA in ma-
ternal plasma and serum would need to be shown to be
present in sufficient quantities for reliable molecular di-
agnosis to be carried out. Second, data on the variation
of fetal DNA concentrations in maternal plasma and
serum, in relation to gestational age, would be required
to determine the applicability of this technology to early
prenatal diagnosis.
We have addressed both of these issues by developing
a real-time quantitative TaqMan PCR assay (Heid et al.
1996) for measuring the copy numbers of fetal DNA
molecules in maternal plasma and serum. This technique
permits continuous optical monitoring of the progress
of an amplification reaction, giving accurate target quan-
titation over a wide concentration range. Our data show
that fetal DNA is present in maternal plasma and serum
at concentrations similar to those achieved by many fetal
cell–enrichment protocols. We have also investigated the
changes of fetal DNA concentration in maternal serum
at different gestational ages. Using this plasma- or se-
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rum-based approach, we show that reliable detection of
fetal DNA is achievable and may potentially be useful
for the noninvasive prenatal diagnosis of selected genetic
disorders.
Subjects and Methods
Subjects
Pregnant women attending the Department of Ob-
stetrics and Gynecology at the Prince of Wales Hospital,
Shatin, Hong Kong were recruited, and informed con-
sent was obtained. The Research Ethics Committee of
the Chinese University of Hong Kong approved the
study protocol. For women studied at a single time point,
early-pregnancy samples were obtained prior to amni-
ocentesis or chorionic villus sampling (CVS), whereas
late-pregnancy samples were collected just prior to de-
livery. We collected 5–10 ml of maternal peripheral
blood into each of two tubes, one of which contained
EDTA. Subjects studied at multiple time points were re-
cruited, prior to conception, from the in vitro fertiliza-
tion (IVF) program. We collected 5–10 ml of maternal
blood from these subjects into a plain tube at each stud-
ied time point. For women undergoing prenatal diag-
nosis, the sex of the fetus was ascertained from cyto-
genetic results from amniocentesis or CVS. For women
recruited just prior to delivery or from the IVF program,
the baby’s sex was noted at the time of delivery.
Preparation of Samples
Blood samples were centrifuged at 3,000g, and plasma
and serum were carefully removed from the EDTA-con-
taining and plain tubes, respectively, and were trans-
ferred into plain polypropylene tubes. Great care was
taken to ensure that the buffy coat or the blood clot was
undisturbed when plasma or serum samples, respec-
tively, were removed. The plasma and serum samples
were recentrifuged at 3,000g, and the supernatants were
collected into fresh polypropylene tubes. The samples
were stored at 20C until further processing.
DNA Extraction from Plasma and Serum Samples
DNA was extracted from plasma and serum samples
by use of a QIAamp Blood Kit (Qiagen) according to
the “blood and body fluid protocol” recommended by
the manufacturer (Chen et al. 1996). We used 400–800
ml of the plasma/serum sample, per column, for DNA
extraction. The exact amounts used were documented,
to enable calculation of target DNA concentration.
Real-Time Quantitative PCR
Theoretical and practical aspects of real-time quan-
titative PCR were described elsewhere by Heid et al.
(1996). Real-time quantitative PCR analysis was per-
formed by use of a PE Applied Biosystems 7700 Se-
quence Detector, which is essentially a combined thermal
cycler/fluorescence detector with the ability to monitor,
optically, the progress of individual PCR reactions. The
amplification and product-reporting system used is
based on the 5′ nuclease assay (Holland et al. 1991) (the
TaqMan assay, Perkin-Elmer). In this system, in addition
to the two amplification primers, as in conventional
PCR, a dual-labeled fluorogenic hybridization probe is
also included (Lee et al. 1993; Livak et al. 1995a). One
fluorescent dye (6 carboxyfluorescein [FAM]) serves as
a reporter, and its emission spectrum is quenched by a
second fluorescent dye (6 carboxy-tetramethylrhoda-
mine [TAMRA]). During the extension phase of PCR,
the 5′ to 3′ exonuclease activity of the Taq DNA poly-
merase cleaves the reporter from the probe, thus releas-
ing it from the quencher, resulting in an increase in fluo-
rescent emission at 518 nm. The PE Applied Biosystems
7700 Sequence Detector is able to measure the fluores-
cent spectra of the 96 amplification wells continuously
during DNA amplification, and the data are captured
onto a Macintosh computer.
The SRY TaqMan system consisted of the amplifica-
tion primers SRY-109F, 5′-TGG CGA TTA AGT CAA
ATT CGC-3′; SRY-245R, 5′-CCC CCT AGT ACC CTG
ACA ATG TAT T-3′; and a dual-labeled fluorescent
TaqMan probe SRY-142T, 5′-(FAM)AGC AGT AGA
GCA GTC AGG GAG GCA GA(TAMRA)-3′. The b-
globin TaqMan system consisted of the amplification
primers b-globin-354F, 5′-GTG CAC CTG ACT CCT
GAG GAG A-3′; b-globin-455R, 5′-CCT TGA TAC
CAA CCT GCC CAG-3′; and a dual-labeled fluorescent
TaqMan probe b-globin-402T, 5′-(FAM)AAG GTG
AAC GTG GAT GAA GTT GGT GG(TAMRA)-3′. The
TaqMan probes contained a 3′-blocking phosphate
group, to prevent probe extension during PCR. Primer/
probe combinations were designed by use of the Primer
Express software (Perkin-Elmer). Sequence data were
obtained from the GenBank Sequence Database (acces-
sion numbers L08063 [SRY gene] and U01317 [b-globin
gene]).
TaqMan amplification reactions were set up in a re-
action volume of 50 ml by use of components (except
TaqMan probes and amplification primers) supplied in
a TaqMan PCR Core Reagent Kit (Perkin-Elmer).
TaqMan probes were custom-synthesized by PE Applied
Biosystems. PCR primers were synthesized by Life Tech-
nologies. Each reaction contained 5 ml of 10# buffer
A; 300 nM of each amplification primer; 100 nM of the
corresponding TaqMan probe; 4 mM MgCl2; 200 mM
each dATP, dCTP, and dGTP; 400 mM dUTP; 1.25 U
AmpliTaq Gold; and 0.5 U AmpErase uracil N-glyco-
sylase. We used 5–10 ml of the extracted plasma/serum
DNA for amplification. The exact amount used was re-
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Figure 1 Real-time quantitative PCR. A, Amplification plots obtained using real-time quantitative PCR for the SRY gene. Each plot
corresponds to a particular input target quantity, marked by a corresponding symbol. The X-axis denotes the cycle number of a quantitative
PCR reaction. The Y-axis denotes the DRn, which is the fluorescence intensity over the background (Heid et al. 1996). B, Plot of the threshold
cycle (CT) against the input target quantity (common log scale). The correlation coefficient is 0.986.
corded, for subsequent concentration calculations. DNA
amplifications were carried out in 96-well reaction plates
that were frosted, by the manufacturer, to prevent light
reflection and were closed by use of caps designed to
prevent light scattering (Perkin-Elmer). Each sample was
analyzed in duplicate. A calibration curve was run in
parallel and in duplicate with each analysis. The con-
version factor of 6.6 pg of DNA per cell was used, for
expression of results as copy numbers.
Identical thermal profiles were used for both the SRY
and the b-globin TaqMan systems. Thermal cycling was
initiated with a 2-min incubation at 50C, to allow the
uracil N-glycosylase to act, followed by a first denatur-
ation step of 10 min at 95C and then 40 cycles of 95C
for 15 s and 60C for 1 minute.
Amplification data collected by the 7700 Sequence
Detector and stored in the Macintosh computer were
then analyzed by use of the Sequence Detection System
software developed by PE Applied Biosystems. Themean
quantity of each duplicate was used for further calcu-
lation. The concentration, expressed in copies per mil-
liliter, was calculated by use of the following equation:
V 1DNAC  Q# # ,
V VPCR ext
whereC target concentration in plasma or serum (cop-
ies per milliliter); Q  target quantity (copies) deter-
mined by sequence detector in PCR;VDNA total volume
of DNA obtained after extraction, typically 50 ml per
Qiagen extraction;VPCR volume of DNA solution used
for PCR, typically 5–10 ml; and Vext volume of plasma
or serum extracted, typically 400–800 ml.
Anticontamination Measures
Strict precautions against PCR contamination were
taken (Kwok and Higuchi 1989). Aerosol-resistant pi-
pette tips were used for all handling of liquids. Separate
areas were used for the preparation of amplification re-
actions, the addition of DNA template, and the carrying
out of amplification reactions. The 7700 Sequence De-
tector offered an extra level of protection in that its
optical detection system obviated the need to reopen the
reaction tubes after completion of the amplification re-
actions, thus minimizing the possibility of carryover con-
tamination. The TaqMan assay also included a further
anticontamination measure in the form of preamplifi-
cation treatment by use of uracil N-glycosylase, which
destroyed uracil-containing PCR products (Longo et al.
1990). Multiple negative water blanks were included in
every analysis.
Results
Development of Real-Time Quantitative PCR
To determine the dynamic range of real-time quanti-
tative PCR, we made serial dilutions of male DNA, in
water, consisting of the DNA equivalent from 1,000 cells
to 1 cell, and we subjected the dilutions to analysis by
the SRY TaqMan system. Figure 1A demonstrates that
the amplification curve shifted to the right as the input
target quantity was reduced. This was expected, since
reactions with fewer target molecules required more am-
plification cycles to produce a certain quantity of re-
porter molecules than did reactions with more target
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Table 1
Quantitative Analysis of Maternal Plasma and Serum by the b-
globin TaqMan Assay
Mean
(copies/ml)
Median
(copies/ml)
Range
(copies/ml)
Plasma (early
late
pregnancy) 3,466 1,594 356–31,875
Serum (early 
late
pregnancy) 50,651 34,688 5,813–243,750
Plasma (early
pregnancy) 986 975 356–1,856
Plasma (late
pregnancy) 5,945 4,313 1,125–31,875
Table 2
Quantitation of Fetal DNA in Maternal Plasma and Serum:
Relationship with Gestational Age
SRY CONCENTRATION (copies/ml)
EARLY PREGNANCY LATE PREGNANCY
Plasma Serum Plasma Serum
Range 3.3–69.4 4.0–58.1 76.9–769 33.8–900
Mean 25.4 28.7 292.2 342.1
Median 20.6 19.5 244.0 286.0
molecules. The system was sensitive enough to detect the
DNA equivalent from a single target cell.
Figure 1B shows a plot of the threshold cycle (CT)
against the input target quantity, with the latter plotted
on a common log scale. The threshold was set at 10 SD
above the mean baseline fluorescence, calculated from
cycles 1–15, and the CT was proportional to the starting
target copy number used for amplification (Heid et al.
1996). The linearity of the graph demonstrates the large
dynamic range and accuracy of real-time quantitative
PCR. Similar results were obtained by use of the b-globin
TaqMan system (data not shown).
The real-time quantitative SRY system was insensitive
to the existence of background female DNA from 0 to
12,800 female genome equivalents. This greatly simpli-
fied the application of this system since, within this
range, separate calibration curves did not have to be
constructed for different cases because of the presence
of different concentrations of fetal and maternal DNA.
The reproducibility of DNA extraction from plasma
and serum with the Qiagen protocol was tested by rep-
licate extractions (10 for each case) from plasma and
serum samples from normal individuals. These replicate
extractions were then subjected to real-time quantitative
PCR by use of the b-globin system. The coefficient of
variation of CT values of these replicate extractions was
1.1%.
Quantitative Analysis using the Real-Time b-globin
TaqMan System
The concentration of b-globin sequences in maternal
plasma and serum samples was used as a measure of the
total amount of extracted DNA, both maternal and fetal.
DNA extracted from plasma and serum samples from
50 pregnant women was analyzed by the b-globin
TaqMan system. Twenty-five pregnant women were re-
cruited during the first and second trimesters (11–17 wk
gestation), and samples were termed “early-pregnancy
samples.” The other 25 women were recruited just prior
to delivery (37–43 wk gestation), and samples were
termed “late-pregnancy samples.” The concentrations of
b-globin sequences in maternal plasma and serum are
listed in table 1. These results show that serum contains
more DNA than plasma (Wilcoxon signed rank test,
), with a mean concentration of serum DNAP ! .0005
14.6 times that of plasma DNA in our studied popu-
lation. The concentration of b-globin sequences in ma-
ternal plasma from early- and late-pregnancy samples
are compared in table 1. These data show that the total
amount of plasma DNA increases as pregnancy pro-
gresses (Mann-Whitney rank sum test, ).P ! .0005
Quantitative Analysis of Fetal SRY Gene from Maternal
Plasma and Serum
Real-time quantitative analysis using the SRYTaqMan
system was carried out on DNA extracted frommaternal
plasma and serum, to determine the amount of fetal
DNA. Of the 25 early-pregnancy samples (11–17 wk
gestation), 13 were from women bearing male fetuses,
and 12 were from women bearing female fetuses. Of the
25 late-pregnancy samples (37–43 wk gestation), 14
were from women bearing male fetuses, and 11 were
from women bearing female fetuses. A positive signal
was obtained for each of the 27 women bearing male
fetuses, and no signal was detected for each of the 23
women bearing female fetuses. Fourteen women had a
history of previous delivery of a male baby, and 5 of
these were carrying a female baby in the current
pregnancy.
Quantitative SRY data from the 27 women bearing
male fetuses are summarized in table 2. These data show
that the concentrations of fetal DNA in plasma and se-
rum are higher in late gestation than in early gestation
(Mann-Whitney rank sum test, ). The meanP ! .0005
concentrations of fetal DNA in maternal plasma and
serum are 11.5 times and 11.9 times higher, respectively,
in late gestation than in early gestation. The absolute
concentrations of fetal DNA in maternal plasma and
serum were similar in individual cases. The fractional
concentration of fetal DNA in early pregnancy is
0.39%–11.9% (mean 3.4%) in plasma and
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0.014%–0.54% (mean 0.13%) in serum. In late preg-
nancy, the fraction of fetal DNA is 2.33%–11.4% (mean
6.2%) in plasma and 0.032%–3.97% (mean 1.0%) in
serum.
Sequential Follow-Up of Women Who Conceived by
IVF
Twenty women who conceived by IVF were followed
up at preconception and at multiple time points during
pregnancy. All 20 subjects had singleton pregnancies, as
determined by ultrasound scanning. Twelve women de-
livered male babies, and the remaining 8 delivered female
babies. None of the women carrying male fetuses had a
history of pregnancy-associated complications. Subject
S-51 (fig. 2) underwent CVS at 12 wk. Subjects S-1 and
S-56 (fig. 2) had amniocentesis at 16 and 17 wk, re-
spectively. A total of 163 serum samples from these 20
women were analyzed by use of the real-time quanti-
tative SRY TaqMan system. None of the 65 serum sam-
ples from the 8 women bearing female babies gave a
positive SRY signal. The concentrations of fetal DNA in
the 98 serum samples from women carrying male babies
are plotted in figure 2.
Discussion
In this study, we have developed an accurate real-time
quantitative PCR system for determining the concentra-
tion of fetal DNA in maternal plasma and serum. This
system has a number of advantages: (1) a large dynamic
range of over five orders of magnitude (Heid et al. 1996);
(2) a high throughput and fast turnaround time—96
samples could be simultaneously amplified and quanti-
fied in ∼2 h; and (3) the use of a homogeneous ampli-
fication/detection system that requires no post-PCR pro-
cessing and therefore minimizes the risk of carryover
contamination.
The most important observation in this study is the
very high concentration of fetal DNA inmaternal plasma
and serum. Bianchi et al. (1997) reported that the av-
erage number of fetal cells in maternal blood in normal
pregnancies was 19 cells/16 ml of maternal blood, or
1.2 cells/ml, during the second trimester. Therefore, the
mean concentration of fetal DNA in maternal plasma
and serum is 21.2 (25.4/1.2) and 23.9 (28.7/1.2) times,
respectively, higher than that in the cellular fraction of
maternal blood at the same gestational stage. The rel-
ative concentration of fetal to total plasma DNA is even
higher. Thus, in early pregnancy, fetal DNA in maternal
plasma constitutes a mean of 3.4% of the total plasma
DNA. The respective figure in late pregnancy is 6.2%.
Hamada et al. (1993) reported that the frequency of fetal
cells in the second trimester was 0.0035%, whereas that
in the third trimester was 0.008%. The fetomaternal
ratio is therefore 970-fold and 775-fold higher in ma-
ternal plasma than in the cellular fraction, at the re-
spective gestational age. Indeed, the fetomaternal ratio
in plasma DNA is comparable to that following many
fetal cell–enrichment protocols. For example, Bianchi et
al. (1994) reported that after fetal nucleated–red cell
enrichment performed with fluorescence-activated cell
sorting, the resulting fetal cells constituted 0.001%–5%
of the sorted cell populations, as determined by quan-
titative PCR analysis. In a similar study using cell sorting
and fetal cell detection by use of fluorescence in situ
hybridization, Sohda et al. (1997) found that, on av-
erage, 4.6% of the sorted cells were of fetal origin. Ma-
ternal plasma, therefore, offers an easily accessible
source of fetal DNA for prenatal genetic analysis.
We have demonstrated that the absolute concentration
of fetal DNA in maternal plasma is similar to that in
maternal serum. The main difference lies in the presence
of a larger quantity of background maternal DNA in
serum compared to plasma, possibly as a result of the
liberation of DNA during the clotting process. Although
this exerts no noticeable effect on the efficiency of fetal
DNA detection by means of the real-time TaqMan sys-
tem, it is possible that, with the use of less sensitive
methods, such as conventional PCR followed by ethi-
dium-stained agarose gel electrophoresis, maternal
plasma may be preferable to maternal serum, for robust
fetal DNA detection.
The high concentration of fetal DNA in maternal
plasma and serum has allowed us to detect reliably the
presence of fetal genetic material. Of the 263 serum or
plasma samples analyzed in this study, we were able to
detect fetal SRY genes in maternal plasma or serum from
every subject who was carrying a male baby at the time
of venesection. This robust detection rate was obtained
with DNA extracted from just 40–80 ml of maternal
plasma and serum. This volume represents a 4–8-fold
increase over the 10 ml of boiled maternal plasma or
serum reported in our previous study (Lo et al. 1997),
and it results in significant improvement in sensitivity.
The specificity was preserved, since we did not observe
amplification signals from samples obtained prior to
conception or from subjects carrying a female fetus.
From the data obtained thus far, plasma/serum analysis
does not appear to be affected significantly by the per-
sistence of fetal cells from previous pregnancies (Bianchi
et al. 1996). Thus, we did not obtain any false-positive
results from women who had previously carried a male
fetus but were carrying a female fetus at the time of
blood sampling for this study.
The sequential study of patients undergoing IVF
yielded a number of important results. First, all of the
12 patients carrying male babies were shown to be neg-
ative for SRY sequences in their sera prior to conception.
This provided convincing evidence that the SRY se-
Lo et al.: Quantitative Analysis of Fetal DNA 773
Figure 2 Sequential study of 12 women, bearing male fetuses, who conceived by IVF. Each case is denoted by a unique recruitment case
number. The X-axis denotes the gestational ages at which serum samples were obtained. A gestational age of zero denotes the preconception
sample. The Y-axis denotes the concentration of fetal SRY in maternal serum, expressed in copies per milliliter. The scale has been optimized
for the concentration range for each case.
quence detected by the TaqMan assay did indeed orig-
inate from the male fetus in the current pregnancy. Sec-
ond, we were able to detect fetal SRY sequences as early
as the 7th wk of gestation, thus indicating that fetal
genetic analysis in maternal plasma/serum could be used
in the first trimester. Third, we showed that fetal DNA
concentration increased as pregnancy progressed (fig. 2).
This last point was also confirmed by data obtained from
women studied at a single time point. Women recruited
late in pregnancy had higher fetal DNA concentrations
in their plasma and serum (table 2).
In addition to the increase in fetal DNA concentration
as pregnancy progresses, our data also indicate that ma-
ternal plasma DNA also increases with gestation (table
1). The biologic basis for this phenomenon is unclear at
present. Possible explanations include the increase in size
of the fetomaternal interface, as gestation progresses,
and a possible reduction in DNA clearance associated
with other physiologic changes during pregnancy.
For selected disorders, fetal genetic information could
be acquired more economically and rapidly from ma-
ternal plasma or serum than by use of fetal cells isolated
from maternal blood. We envisage that fetal DNA anal-
ysis in maternal plasma and serum would be most useful
in situations where the determination of fetal-derived
paternally-inherited polymorphisms/mutations or genes
would be helpful in clinical prenatal diagnosis (Lo et al.
1994). Examples include fetal sex determination, for
774 Am. J. Hum. Genet. 62:768–775, 1998
prenatal diagnosis of sex-linked disorders; fetal rhesus
D status determination in sensitized rhesus-negative
pregnant women (Lo et al. 1993); autosomal dominant
disorders in which the father carries the mutation; and
autosomal recessive genetic disorders in which the father
and mother carry different mutations (Lo et al.
1994)—for example, certain hemoglobinopathies (Ca-
maschella et al. 1990) and cystic fibrosis. Because of the
much-reducedmaternal background and high fetal DNA
concentration in maternal plasma and serum, we predict
that this type of analysis would be much more robust
when based on plasma or serum DNA than when un-
sorted fetal cells in maternal blood are used. The ability
for allelic discrimination (Lee et al. 1993; Livak et al.
1995b) allows the homogeneous TaqMan assay to be
used for this purpose. The high throughput and anti-
contamination capability of this system makes it an at-
tractive candidate for large-scale clinical application.
Bianchi et al. (1997) recently reported that fetal cells
in maternal blood were increased in aneuploid pregnan-
cies, and it would be very interesting to investigate
whether the fetal DNA concentration in maternal
plasma and serum would also be elevated in these preg-
nancies. This would potentially provide a new screening
test for fetal chromosomal disorders. For this potential
application, fetal DNA quantitation systems must be de-
veloped for polymorphic markers outside the Y chro-
mosome so that quantitation can be applied to female
fetuses. Autosomal polymorphic systems that might be
used for this purpose have already been described (Lo
et al. 1996). However, fetal cell isolation techniques
would still be necessary for a definitive cytogenetic di-
agnosis. Similarly, fetal cell isolation would also be re-
quired for direct mutational analysis of autosomal re-
cessive disorders caused by a single mutation. It is likely
that fetal cell isolation and analysis of fetal DNA in
maternal plasma/serum would be used as complemen-
tary techniques for noninvasive prenatal diagnosis.
The biological basis by which fetal DNA is liberated
into maternal plasma remains to be elucidated. It is pos-
sible that fetal DNA is released from cell lysis resulting
from physical and immunologic damage or through de-
velopmentally associated apoptosis of fetal tissues. It is
also likely that increased amounts of fetal DNA may be
found in conditions associated with placental damage,
such as pre-eclampsia. The real-time quantitative PCR
system described here offers a powerful tool to study
these unexplored pathophysiologic aspects of fetal DNA
in maternal plasma, and it may improve our understand-
ing of the fetomaternal relationship.
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